We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval.
- Authors
Pascart, Tristan; Norberciak, Laurène; Ea, Hang-Korng; Graf, Sahara; Guggenbuhl, Pascal; Lioté, Frédéric
- Abstract
Objective The objective was to determine the proportion of patients with difficult-to-treat or difficult-to-prevent acute gout attacks eligible for IL-1 inhibition. Methods Participants included in the French cross-sectional GOSPEL cohort (n = 1003 gout patients) were examined for contraindications and intolerance to standard of care (SoC) drugs of gout flares (colchicine, non-steroidal anti-inflammatory drugs and systemic glucocorticoids). Patients were classified as definitely eligible for first-line IL-1 inhibition (canakinumab) according to European summary of product characteristics (contraindications/intolerance to SoC and at least three flares per year) without any other anti-inflammatory options (contraindications/intolerance only), or potentially eligible (precaution of use). Eligibility to receive IL-1 during an on-going flare related to insufficient efficacy was assessed (second-line eligibility). Results Definite first-line eligibility for IL-1 therapy was found in 10 patients (1%) and contraindication to all SoC therapies in nine patients who had presented <3 flares in the past 12 months. At least precaution of use for SoC therapies was noted for 218/1003 patients (21.7%). Of 487 patients experiencing flares at baseline, 114 (23.4%) were still experiencing pain scored ⩾4/10 numeric scale on day 3, one of whom could not receive further SoC drugs. Only nine of them had three or more flares in the past year and were eligible for second-line IL-1 inhibition. Conclusion Despite significant numbers of patients without any SoC anti-inflammatory therapeutic options for gout flares, eligibility for IL-1 inhibition therapy according to current European approval is rare.
- Subjects
EUROPE; THERAPEUTIC use of glucocorticoids; NONSTEROIDAL anti-inflammatory agents; COLCHICINE; GOUT; INTERLEUKIN-1; MEDICAL practice; ELIGIBILITY (Social aspects); DRUG approval; DESCRIPTIVE statistics
- Publication
Rheumatology, 2019, Vol 58, Issue 12, p2181
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/kez203